Pharmaceutical Raw Materials Mitotan CAS 53-19-0 Used to Antineoplastic Agent
Unit Price:Get Latest Price >
Purchase Qty: (Gram(s))10+

Payment Terms: T/TWestern Union, MoneyGram,Bitcoin

Add to Favorites

Guangzhou Kafen Biotech Co.,Ltd

No.128,Hanxing East Rd,Zhongcun,Panyu District,Guangzhou,Guangdong,China

Guangzhou,Guangdong 511495



Please sign in to see details

Main Product:

Steroids,SARM,Peptides,Pharmaceutical Raw Materials,Pharmaceutical Intermediates

Quick Details

Country of Origin:  United Kingdom

CAS No.:  53-19-0

Purity:  99%

Appearance:  White Powder

Brand:  kafen

Model:  53-19-0

Molecular formula:  C14H10Cl4

Average Lead Time:  Within 12 hours after receiving your payment

Packaging Detail:  According to your requirements

Product Description

Pharmaceutical Raw Materials Mitotan CAS 53-19-0 Used to Antineoplastic Agent

Basic info:

Air & Water Reactions:Insoluble in water.
Chemical Properties:White Crystalline Solid
Usage:insecticide, antineoplastic. treatment of osteoporosis and Paget's bone disease. Used as an adrenolytic agent

Product info:

Mitotane Simple aromatic halogenated organic compounds are very unreactive; halogenated aliphatic compounds are moderately or very reactive. For both subgroups, reactivity generally decreases with increased degree of substitution of halogen for hydrogen atoms. Materials in this group are incompatible with strong oxidizing and reducing agents. Also, they are incompatible with many amines, nitrides, azo/diazo compounds, alkali metals, and epoxides.

Product Avail:

Mitotane structure and pharmacological action insecticide DDT (DDT) and DDD similar, it selectively adrenal zona fasciculata and reticularis cells atrophy, necrosis, but does not affect the zona, aldosterone secretion and therefore will not be affected. Blood and urine cortisol and its metabolites rapidly reduced after treatment, the body adrenocorticotropic hormone and metabolism products decreased rapidly, for the treatment of inoperable, functional and non-functional adrenal cortical carcinoma, adrenal tumor, adrenal gland cruzi induced hyperplasia syndrome, adrenal hyperplasia, cortical cancer adjuvant therapy and tumor-induced Cushing's syndrome.